000145046 001__ 145046 000145046 005__ 20250923084441.0 000145046 0247_ $$2doi$$a10.1016/j.pcad.2024.06.001 000145046 0248_ $$2sideral$$a139861 000145046 037__ $$aART-2024-139861 000145046 041__ $$aeng 000145046 100__ $$0(orcid)0000-0002-7865-3429$$aLópez-Bueno, Rubén$$uUniversidad de Zaragoza 000145046 245__ $$aDose-response associations of the American Heart Association's new “Life's essential 8” metrics with all-cause and cardiovascular mortality in a nationally representative sample from the United States 000145046 260__ $$c2024 000145046 5203_ $$aBackground: Our aim was to examine the prospective dose-response associations of American Heart Association's (AHA) LIFE's Essential 8 (LE8) score and number of cardiovascular health (CVH) factors with high score with all-cause and cardiovascular disease (CVD) related mortality. Methods: We pooled 6 consecutive waves of the National Health and Nutrition Examination Survey (NHANES) comprising rounds between 2007 and 2008 and 2017–2018. We calculated hazard ratios (HRs) and conducted restricted cubic splines models to assess the dose-response association of LE8 score and CVH factors with all-cause and CVD mortality. Results: Analyses included 23,531 adults aged 18 years and over (mean [SD] age, 43.6 [16.7] years; 11,979 [51%] female; 8960 [38.1%] non-Hispanic white individuals) with a median follow-up of 7.3 years (IQR 4.3–10.1), corresponding to 168,033 person-years. The dose-response analyses showed a significant inverse curvilinear trend for the association between LE8 score with all-cause and CVD mortality. The optimal risk reduction for all-cause mortality was found at 100 points of the LE8 Score (HR, 0.50; 95% CI, 0.27–0.93) compared to the reference (median LE8 score [62.5 points]). Moreover, the dose-response association between LE8 and CVD mortality also exhibited a significant inverse curvilinear association up to 90 points (HR, 0.41; 95% CI, 0.17–0.99). Optimal levels of LE8 score may be able to avert around 40% of the annual all-cause and CVD deaths among the US adult population. Conclusions: Best-case scenario of CVH may reduce around 40% of the all-cause and CVD annual mortality among adults in the United States. 000145046 540__ $$9info:eu-repo/semantics/closedAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/ 000145046 590__ $$a7.6$$b2024 000145046 592__ $$a1.815$$b2024 000145046 591__ $$aCARDIAC & CARDIOVASCULAR SYSTEMS$$b22 / 230 = 0.096$$c2024$$dQ1$$eT1 000145046 593__ $$aCardiology and Cardiovascular Medicine$$c2024$$dQ1 000145046 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000145046 700__ $$aCalatayud, Joaquín 000145046 700__ $$aPozo Cruz, Jesús del 000145046 700__ $$aYang, Lin 000145046 700__ $$aPozo Cruz, Borja del 000145046 7102_ $$13001$$2187$$aUniversidad de Zaragoza$$bDpto. Expres.Music.Plást.Corp.$$cÁrea Didáctica Expres.Corporal 000145046 773__ $$g85 (2024), 31-37$$pProg. cardiovasc. dis.$$tPROGRESS IN CARDIOVASCULAR DISEASES$$x0033-0620 000145046 8564_ $$s829597$$uhttps://zaguan.unizar.es/record/145046/files/texto_completo.pdf$$yVersión publicada 000145046 8564_ $$s2139507$$uhttps://zaguan.unizar.es/record/145046/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000145046 909CO $$ooai:zaguan.unizar.es:145046$$particulos$$pdriver 000145046 951__ $$a2025-09-22-14:50:32 000145046 980__ $$aARTICLE